Promise Bio

Promise Bio is advancing precision medicine in IBD using the first AI-powered broad-epiproteomics platform. The platform detects over 60 post-translational modifications (PTMs) directly from standard mass spectrometry data (without enrichment) and creates comprehensive proteoform profiles at significantly greater speed. By linking PTMs to functional biology through our EpiTome data lake, we uncover mechanistic insights into immune signaling, epithelial barrier dysfunction, and tissue remodeling that are often missed by abundance-based analyses. The PromiseOS suite enables earlier and more precise biomarker discovery, improved patient stratification, and a deeper understanding of disease mechanisms, ultimately supporting more informed therapeutic development and better outcomes for IBD patients.